Table 2 from Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Semantic Scholar
PEACE-1: OS in mCSPC - Capsule Summary Slidesets - ESMO 2021 - Oncology - Clinical Care Options
Mapping Pathways for PARP Inhibition in Prostate Cancer: Practical Considerations for Clinical Practice | ESMO
Is Earlier Better? Translating Clinical Evidence into Individualised Treatment Decisions in Advanced Prostate Cancer | ESMO
ESMO 2020: PARP inhibitor olaparib for the targeted treatment of metastatic prostate cancer - ecancer
Prostate Cancer Highlights from ESMO 2022 - YouTube
Women for Mankind: Optimal Use of Chemotherapy in Metastatic Prostate Cancer | ESMO
Guidelines for genetic testing
Advanced Prostate Cancer: How Do We Move Forward in Patient Management? | ESMO
Actionable Targets In Advanced Prostate Cancer: The Potential of Molecular Profiling and Radioligand Therapy | ESMO
Prostate cancer: data support adding ADT for patients undergoing post-operative radiotherapy - Daily Reporter
ESMO 2022: Metastatic Castration-Sensitive Prostate Cancer 2022 Updates Discussion
Application of Liquid Biopsy Webinar Series – Prostate Cancer
ESMO Preceptorship on Prostate Cancer | Lugano 2019
ESMO Preceptorship on Prostate Cancer 2022: Lugano
ESMO Virtual Advanced Course on Clinical Questions in Prostate
ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival With Abiraterone Acetate Plus Prednisone in PEACE-1
Updated Therapeutic Approach of Castration-Resistant Prostate Cancer (CRPC) | ESMO
Elucidate Metastatic Prostate Cancer Targets with Radioligand Therapy and Molecular Profiling: Advancing Precision Medicine in Prostate Cancer | ESMO
ESMO 2019: Invited Discussant: The CARD Trial – Cabazitaxel as Third Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Philippine Endourological Society
ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
